Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related SNTS
UPDATE: Stifel Downgrades Santarus Following SLXP Acquisition
Benzinga's Top Downgrades
Related SLXP
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
Valeant Pharmaceuticals Is Kicking Butt, Says Canaccord Genuity
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report (Seeking Alpha)

Janney Capital initiated coverage on shares of Salix Pharmaceuticals (NASDAQ: SLXP) with a “buy” rating. The target price for Salix is set to $55. Salix's shares closed at $47.21 yesterday.

Analysts at Leerink initiated coverage on shares of Santarus (NASDAQ: SNTS) with a “outperform” rating. Santarus' shares closed at $12.93 yesterday.

JP Morgan initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ: INFI) with an “overweight” rating. The target price for Infinity Pharmaceuticals is set to $42. Infinity Pharmaceuticals' stock closed at $33.37 yesterday.

Analysts at Janney Capital initiated coverage on shares of Forest Laboratories (NYSE: FRX) with a “buy” rating. The target price for Forest Labs is set to $45. Forest Labs' shares closed at $36.28 yesterday.

Latest Ratings for SNTS

DateFirmActionFromTo
Dec 2013Stifel NicolausDowngradesBuyHold
Nov 2013Roth CapitalDowngradesBuyNeutral
Nov 2013Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for SNTS
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (INFI + FRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→